Welcome to Chinese Journal of Clinical Pharmacology and Therapeutics,Today is Share:

Chinese Journal of Clinical Pharmacology and Therapeutics ›› 2022, Vol. 27 ›› Issue (11): 1292-1298.doi: 10.12092/j.issn.1009-2501.2022.11.012

Previous Articles     Next Articles

Role of vitamin D and ACE2 in COVID-19

TANG Jiawei, MENG Xiangzhe, SUN Xuemin, LI Yuexuan, LIU Xue, WEI Hong   

  1. School of Basic Medicine Sciences, Jining Medical University, Jining 272067, Shandong, China
  • Received:2022-10-24 Revised:2022-12-02 Online:2022-11-26 Published:2022-12-12

Abstract:

The spread of COVID-19 has greatly threatened human health and economic growth. Angiotensin-converting enzyme 2 (ACE2) is a receptor for severe acute respiratory syndrome coronavirus 2 (SARS-COV-2). By attaching to ACE2, SARS-COV-2 reduces its expression and induces lung injury. Vitamin D can inhibit the progression of COVID-19 by inhibiting the activity of ROCK pathway, up-regulating ACE2 expression and bioavailability, and slowing down the adverse reactions caused by AngⅡ accumulation. This study explored a novel mechanism, i.e., vitamin D protects against COVID-19-induced injury by upregulating ACE2 expression. It provides theoretical guidance for the role of Vitamin D in the prevention and treatment of COVID-19.

Key words: angiotensin-converting enzyme 2, vitamin D, SARS-CoV-2, COVID-19

CLC Number: